Baidu
map

心血管

订阅

MedSci主页 / 所有栏目 / 心血管

新型降脂药Alirocumab获FDA批准和欧洲CHMP批准建议

2015-07-29 小许 编译 中国医学论坛报

新型降脂药Alirocumab
关注

正如业内广泛预期，6月24日新型降低密度脂蛋白胆固醇(LDL-C)药物Alirocumab(Praluent)获得美国食品与药物管理局(FDA)批准。该药的适应证为杂合子家族性高胆固醇血症的治疗或他汀治疗无效的心血管高危人群。 alirocumab是第一个获得FDA批准的PCSK9抑制剂，尽管业内广泛预期FDA会在接下来几周之内批准另一种PCSK9抑制剂evolocumab。据heartwire

正如业内广泛预期，6月24日新型降低密度脂蛋白胆固醇(LDL-C)药物Alirocumab(Praluent)获得美国食品与药物管理局(FDA)批准。该药的适应证为杂合子家族性高胆固醇血症的治疗或他汀治疗无效的心血管高危人群。

alirocumab是第一个获得FDA批准的PCSK9抑制剂，尽管业内广泛预期FDA会在接下来几周之内批准另一种PCSK9抑制剂evolocumab。据heartwire报道，今年6月，alirocumab已经获得FDA内分泌和代谢药物咨询委员会(EMDAC)的批准建议。更早之前，该药物也获得了欧洲药品局人用医药产品委员会(CHMP)的批准建议。该建议目前正提交至欧盟委员会(EC)，EC将最终决定是否alirocumab可在欧洲上市。EC不久前批准了alirocumab的竞争产品evolocumab。

截止目前，alirocumab的心血管预后试验仍在进行中。ODYSSEY-Outcomes试验的主要终点包括冠心病死亡、任何非致死性心梗、致死和非致死性缺血性卒中和需住院治疗的不稳定性心绞痛，计划于2017年12月结束评估。次要终点包括任何冠心病事件的首次发作、主要冠心病事件、任何心血管事件和全因死亡率。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (16)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1976886, encodeId=b78e19e68862e, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Mon Dec 28 09:58:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911706, encodeId=e12c1911e0684, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Dec 18 09:58:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839383, encodeId=24f1183938322, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Feb 09 19:58:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34014, encodeId=2dfc340146c, content=他汀不耐受患者的新出路, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Sat Aug 01 19:58:00 CST 2015, time=2015-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302634, encodeId=b9e913026349a, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338948, encodeId=77711338948c9, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348369, encodeId=2898134836992, content=<a href='/topic/show?id=9f7198199df' target=_blank style='color:#2F92EE;'>#降脂药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98199, encryptionId=9f7198199df, topicName=降脂药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378604, encodeId=b19013e8604f4, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2305, encryptionId=e7f523050b, topicName=Alirocumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33892, encodeId=f44a338921f, content=太好了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150607/IMG557444368BC809744.jpg, createdBy=98b61614917, createdName=lindsey0301, createdTime=Thu Jul 30 21:40:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33861, encodeId=5cf73386161, content=好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:00:00 CST 2015, time=2015-07-30, status=1, ipAttribution=)]
    2015-12-28 linlin2312

    #ROC#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1976886, encodeId=b78e19e68862e, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Mon Dec 28 09:58:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911706, encodeId=e12c1911e0684, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Dec 18 09:58:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839383, encodeId=24f1183938322, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Feb 09 19:58:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34014, encodeId=2dfc340146c, content=他汀不耐受患者的新出路, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Sat Aug 01 19:58:00 CST 2015, time=2015-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302634, encodeId=b9e913026349a, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338948, encodeId=77711338948c9, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348369, encodeId=2898134836992, content=<a href='/topic/show?id=9f7198199df' target=_blank style='color:#2F92EE;'>#降脂药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98199, encryptionId=9f7198199df, topicName=降脂药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378604, encodeId=b19013e8604f4, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2305, encryptionId=e7f523050b, topicName=Alirocumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33892, encodeId=f44a338921f, content=太好了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150607/IMG557444368BC809744.jpg, createdBy=98b61614917, createdName=lindsey0301, createdTime=Thu Jul 30 21:40:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33861, encodeId=5cf73386161, content=好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:00:00 CST 2015, time=2015-07-30, status=1, ipAttribution=)]
    2015-12-18 snf701207

    #mAb#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1976886, encodeId=b78e19e68862e, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Mon Dec 28 09:58:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911706, encodeId=e12c1911e0684, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Dec 18 09:58:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839383, encodeId=24f1183938322, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Feb 09 19:58:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34014, encodeId=2dfc340146c, content=他汀不耐受患者的新出路, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Sat Aug 01 19:58:00 CST 2015, time=2015-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302634, encodeId=b9e913026349a, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338948, encodeId=77711338948c9, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348369, encodeId=2898134836992, content=<a href='/topic/show?id=9f7198199df' target=_blank style='color:#2F92EE;'>#降脂药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98199, encryptionId=9f7198199df, topicName=降脂药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378604, encodeId=b19013e8604f4, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2305, encryptionId=e7f523050b, topicName=Alirocumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33892, encodeId=f44a338921f, content=太好了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150607/IMG557444368BC809744.jpg, createdBy=98b61614917, createdName=lindsey0301, createdTime=Thu Jul 30 21:40:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33861, encodeId=5cf73386161, content=好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:00:00 CST 2015, time=2015-07-30, status=1, ipAttribution=)]
    2016-02-09 bugit

    #FDA批准#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1976886, encodeId=b78e19e68862e, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Mon Dec 28 09:58:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911706, encodeId=e12c1911e0684, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Dec 18 09:58:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839383, encodeId=24f1183938322, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Feb 09 19:58:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34014, encodeId=2dfc340146c, content=他汀不耐受患者的新出路, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Sat Aug 01 19:58:00 CST 2015, time=2015-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302634, encodeId=b9e913026349a, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338948, encodeId=77711338948c9, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348369, encodeId=2898134836992, content=<a href='/topic/show?id=9f7198199df' target=_blank style='color:#2F92EE;'>#降脂药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98199, encryptionId=9f7198199df, topicName=降脂药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378604, encodeId=b19013e8604f4, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2305, encryptionId=e7f523050b, topicName=Alirocumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33892, encodeId=f44a338921f, content=太好了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150607/IMG557444368BC809744.jpg, createdBy=98b61614917, createdName=lindsey0301, createdTime=Thu Jul 30 21:40:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33861, encodeId=5cf73386161, content=好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:00:00 CST 2015, time=2015-07-30, status=1, ipAttribution=)]
    2015-08-01 Messichen1992

    他汀不耐受患者的新出路

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1976886, encodeId=b78e19e68862e, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Mon Dec 28 09:58:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911706, encodeId=e12c1911e0684, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Dec 18 09:58:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839383, encodeId=24f1183938322, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Feb 09 19:58:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34014, encodeId=2dfc340146c, content=他汀不耐受患者的新出路, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Sat Aug 01 19:58:00 CST 2015, time=2015-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302634, encodeId=b9e913026349a, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338948, encodeId=77711338948c9, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348369, encodeId=2898134836992, content=<a href='/topic/show?id=9f7198199df' target=_blank style='color:#2F92EE;'>#降脂药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98199, encryptionId=9f7198199df, topicName=降脂药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378604, encodeId=b19013e8604f4, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2305, encryptionId=e7f523050b, topicName=Alirocumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33892, encodeId=f44a338921f, content=太好了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150607/IMG557444368BC809744.jpg, createdBy=98b61614917, createdName=lindsey0301, createdTime=Thu Jul 30 21:40:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33861, encodeId=5cf73386161, content=好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:00:00 CST 2015, time=2015-07-30, status=1, ipAttribution=)]
    2015-07-31 医生2394

    #CHMP#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1976886, encodeId=b78e19e68862e, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Mon Dec 28 09:58:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911706, encodeId=e12c1911e0684, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Dec 18 09:58:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839383, encodeId=24f1183938322, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Feb 09 19:58:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34014, encodeId=2dfc340146c, content=他汀不耐受患者的新出路, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Sat Aug 01 19:58:00 CST 2015, time=2015-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302634, encodeId=b9e913026349a, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338948, encodeId=77711338948c9, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348369, encodeId=2898134836992, content=<a href='/topic/show?id=9f7198199df' target=_blank style='color:#2F92EE;'>#降脂药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98199, encryptionId=9f7198199df, topicName=降脂药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378604, encodeId=b19013e8604f4, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2305, encryptionId=e7f523050b, topicName=Alirocumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33892, encodeId=f44a338921f, content=太好了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150607/IMG557444368BC809744.jpg, createdBy=98b61614917, createdName=lindsey0301, createdTime=Thu Jul 30 21:40:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33861, encodeId=5cf73386161, content=好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:00:00 CST 2015, time=2015-07-30, status=1, ipAttribution=)]
    2015-07-31 ms9474365431325850

    #欧洲#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1976886, encodeId=b78e19e68862e, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Mon Dec 28 09:58:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911706, encodeId=e12c1911e0684, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Dec 18 09:58:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839383, encodeId=24f1183938322, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Feb 09 19:58:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34014, encodeId=2dfc340146c, content=他汀不耐受患者的新出路, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Sat Aug 01 19:58:00 CST 2015, time=2015-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302634, encodeId=b9e913026349a, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338948, encodeId=77711338948c9, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348369, encodeId=2898134836992, content=<a href='/topic/show?id=9f7198199df' target=_blank style='color:#2F92EE;'>#降脂药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98199, encryptionId=9f7198199df, topicName=降脂药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378604, encodeId=b19013e8604f4, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2305, encryptionId=e7f523050b, topicName=Alirocumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33892, encodeId=f44a338921f, content=太好了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150607/IMG557444368BC809744.jpg, createdBy=98b61614917, createdName=lindsey0301, createdTime=Thu Jul 30 21:40:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33861, encodeId=5cf73386161, content=好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:00:00 CST 2015, time=2015-07-30, status=1, ipAttribution=)]
    2015-07-31 Boyinsh

    #降脂药#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1976886, encodeId=b78e19e68862e, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Mon Dec 28 09:58:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911706, encodeId=e12c1911e0684, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Dec 18 09:58:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839383, encodeId=24f1183938322, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Feb 09 19:58:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34014, encodeId=2dfc340146c, content=他汀不耐受患者的新出路, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Sat Aug 01 19:58:00 CST 2015, time=2015-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302634, encodeId=b9e913026349a, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338948, encodeId=77711338948c9, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348369, encodeId=2898134836992, content=<a href='/topic/show?id=9f7198199df' target=_blank style='color:#2F92EE;'>#降脂药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98199, encryptionId=9f7198199df, topicName=降脂药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378604, encodeId=b19013e8604f4, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2305, encryptionId=e7f523050b, topicName=Alirocumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33892, encodeId=f44a338921f, content=太好了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150607/IMG557444368BC809744.jpg, createdBy=98b61614917, createdName=lindsey0301, createdTime=Thu Jul 30 21:40:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33861, encodeId=5cf73386161, content=好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:00:00 CST 2015, time=2015-07-30, status=1, ipAttribution=)]
    2015-07-31 30397604

    #Alirocumab#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1976886, encodeId=b78e19e68862e, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Mon Dec 28 09:58:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911706, encodeId=e12c1911e0684, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Dec 18 09:58:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839383, encodeId=24f1183938322, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Feb 09 19:58:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34014, encodeId=2dfc340146c, content=他汀不耐受患者的新出路, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Sat Aug 01 19:58:00 CST 2015, time=2015-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302634, encodeId=b9e913026349a, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338948, encodeId=77711338948c9, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348369, encodeId=2898134836992, content=<a href='/topic/show?id=9f7198199df' target=_blank style='color:#2F92EE;'>#降脂药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98199, encryptionId=9f7198199df, topicName=降脂药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378604, encodeId=b19013e8604f4, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2305, encryptionId=e7f523050b, topicName=Alirocumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33892, encodeId=f44a338921f, content=太好了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150607/IMG557444368BC809744.jpg, createdBy=98b61614917, createdName=lindsey0301, createdTime=Thu Jul 30 21:40:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33861, encodeId=5cf73386161, content=好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:00:00 CST 2015, time=2015-07-30, status=1, ipAttribution=)]
    2015-07-30 lindsey0301

    太好了！

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1976886, encodeId=b78e19e68862e, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Mon Dec 28 09:58:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911706, encodeId=e12c1911e0684, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Dec 18 09:58:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839383, encodeId=24f1183938322, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Feb 09 19:58:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=34014, encodeId=2dfc340146c, content=他汀不耐受患者的新出路, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed101627734, createdName=Messichen1992, createdTime=Sat Aug 01 19:58:00 CST 2015, time=2015-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302634, encodeId=b9e913026349a, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338948, encodeId=77711338948c9, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348369, encodeId=2898134836992, content=<a href='/topic/show?id=9f7198199df' target=_blank style='color:#2F92EE;'>#降脂药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98199, encryptionId=9f7198199df, topicName=降脂药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378604, encodeId=b19013e8604f4, content=<a href='/topic/show?id=e7f523050b' target=_blank style='color:#2F92EE;'>#Alirocumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2305, encryptionId=e7f523050b, topicName=Alirocumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jul 31 00:58:00 CST 2015, time=2015-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33892, encodeId=f44a338921f, content=太好了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150607/IMG557444368BC809744.jpg, createdBy=98b61614917, createdName=lindsey0301, createdTime=Thu Jul 30 21:40:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33861, encodeId=5cf73386161, content=好！, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:00:00 CST 2015, time=2015-07-30, status=1, ipAttribution=)]
    2015-07-30 shenyifeiyang

    好！

    0

以上为热门评论，梅斯医学App还有更多内容
Baidu
map
Baidu
map
Baidu
map